MX2024011666A - Inmunosupresion especifica de acuaporina 4 (aqp4) mediada por mhc ib como nuevo tratamiento para la nmo. - Google Patents

Inmunosupresion especifica de acuaporina 4 (aqp4) mediada por mhc ib como nuevo tratamiento para la nmo.

Info

Publication number
MX2024011666A
MX2024011666A MX2024011666A MX2024011666A MX2024011666A MX 2024011666 A MX2024011666 A MX 2024011666A MX 2024011666 A MX2024011666 A MX 2024011666A MX 2024011666 A MX2024011666 A MX 2024011666A MX 2024011666 A MX2024011666 A MX 2024011666A
Authority
MX
Mexico
Prior art keywords
nmo
mhc
aqp4
novel treatment
specific immunosuppression
Prior art date
Application number
MX2024011666A
Other languages
English (en)
Spanish (es)
Inventor
Valentin Bruttel
Jörg Wischhusen
Fadhil Ahsan
Shriya Mamatha Jayaram
Original Assignee
Univ Wuerzburg J Maximilians
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Wuerzburg J Maximilians filed Critical Univ Wuerzburg J Maximilians
Publication of MX2024011666A publication Critical patent/MX2024011666A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2024011666A 2022-03-24 2023-03-24 Inmunosupresion especifica de acuaporina 4 (aqp4) mediada por mhc ib como nuevo tratamiento para la nmo. MX2024011666A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP22164161.6A EP4249062A1 (en) 2022-03-24 2022-03-24 Mhc ib-mediated aquaporin 4 (aqp4)-specific immunosuppression as a novel treatment for nmo
PCT/EP2023/057684 WO2023180549A1 (en) 2022-03-24 2023-03-24 Mhc ib-mediated aquaporin 4 (aqp4)-specific immunosuppression as a novel treatment for nmo

Publications (1)

Publication Number Publication Date
MX2024011666A true MX2024011666A (es) 2024-09-27

Family

ID=81325683

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024011666A MX2024011666A (es) 2022-03-24 2023-03-24 Inmunosupresion especifica de acuaporina 4 (aqp4) mediada por mhc ib como nuevo tratamiento para la nmo.

Country Status (12)

Country Link
US (1) US20250205322A1 (enExample)
EP (2) EP4249062A1 (enExample)
JP (1) JP2025510786A (enExample)
KR (1) KR20240164796A (enExample)
CN (1) CN119110810A (enExample)
AU (1) AU2023237632A1 (enExample)
CA (1) CA3250911A1 (enExample)
CL (1) CL2024002725A1 (enExample)
CO (1) CO2024012332A2 (enExample)
IL (1) IL314754A (enExample)
MX (1) MX2024011666A (enExample)
WO (1) WO2023180549A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025061917A1 (en) * 2023-09-22 2025-03-27 Julius-Maximilians-Universität Würzburg Mhc ib-mediated aquaporin 4 (aqp4)-specific immunosuppression as a novel treatment for nmo

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9234017B2 (en) * 2012-12-11 2016-01-12 The Regents Of The University Of California Aquaporin-4 peptide compositions and methods of use thereof
SG11201909290TA (en) * 2017-04-07 2019-11-28 Uti Lp Assay to measure the potency of receptor-ligand interactions in nanomedicines
CA3063959A1 (en) 2017-05-23 2018-11-29 Julius-Maximilians-Universitat Wurzburg Combinations of mhc class ib molecules and peptides for targeted therapeutic immunomodulation
WO2021184017A1 (en) * 2020-03-13 2021-09-16 Codiak Biosciences, Inc. Extracellular vesicles for treating neurological disorders

Also Published As

Publication number Publication date
CO2024012332A2 (es) 2024-09-30
CA3250911A1 (en) 2023-09-28
US20250205322A1 (en) 2025-06-26
EP4249062A1 (en) 2023-09-27
KR20240164796A (ko) 2024-11-20
WO2023180549A1 (en) 2023-09-28
AU2023237632A1 (en) 2024-08-15
CN119110810A (zh) 2024-12-10
CL2024002725A1 (es) 2025-02-14
EP4499231A1 (en) 2025-02-05
IL314754A (en) 2024-10-01
JP2025510786A (ja) 2025-04-15

Similar Documents

Publication Publication Date Title
Scala et al. Accessory cell function of human B cells. I. Production of both interleukin 1-like activity and an interleukin 1 inhibitory factor by an EBV-transformed human B cell line.
WO2022081718A8 (en) Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
DE69332413D1 (de) Interleukin-2 analoge mit niedriger toxizität zur verwendung in der immuntherapie
CY1110848T1 (el) Αντισωμα αντι ανθρωπου νοgo α kai h φαρμακευτικη του χρηση
WO2022036142A3 (en) Ras neoantigens and uses thereof
IL310372A (en) Il15/il15r alpha heterodimeric fc-fusion proteins for the treatment of blood cancers
MX2024014979A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer
MX2025006929A (es) Anticuerpos contra la proteína 1 que contiene dominio de cub (cdcp1) y usos de estos
AU4104700A (en) Antibody and chemokine constructs that are directed to CCR5, and their use for treating autoimmune diseases
MX2023003890A (es) Molecula de interleucina-2 (il-2) modificada y uso de la misma.
WO2023180546A8 (en) Mhc ib-mediated myelin-specific immunosuppression as a novel treatment for multiple sclerosis and mog antibody disease
MX2024011665A (es) Induccion de tolerancia especifica de alfa-sinucleina mediada por mhc ib como nuevo tratamiento para la enfermedad de parkinson.
CO2024012332A2 (es) Inmunosupresión específica de acuaporina 4 (aqp4) mediada por mhc ib como nuevo tratamiento para la nmo
de Oliveira Silva et al. Immunostimulatory activity of ConBr: a focus on splenocyte proliferation and proliferative cytokine secretion
MX2024011668A (es) Inmunosupresion especifica del antigeno de los islotes mediada por mhc ib como nuevo tratamiento para la diabetes tipo 1.
US20020159969A1 (en) Small peptide-based therapeutics for reversing cancer-associated MUC-1 mucin-induced immunosuppression
Pelletier et al. Modulation of interleukin-15-induced human neutrophil responses by the plant lectin Viscum album agglutinin-I
AU631674B2 (en) Pokeweed antiviral protein - monoclonal antibody conjugates
Dullens et al. Anti-tumour effect of chlorambucil-antibody complexes in a murine melanoma system
Izquierdo et al. Selective T cell subset depletion with anti-CD4 and anti-CD8 intact ricin immunotoxins
Saxena et al. Partial purification and characterization of a novel human factor that augments the expression of class I MHC antigens on tumour cells
RU2724714C1 (ru) Способ конъюгации константного фрагмента тяжелой цепи антитела человека и пептоидного аналога аутоантигена mog35-55 для терапии рассеянного склероза
MX2024013887A (es) Composiciones que comprenden interleucina-33 truncada e interleucina-2
EP1369428A1 (en) Muc-1 derivatives and their use in treating cancer-associated MUC-1 Mucin-induced immunosuppression
WO2025222087A3 (en) Klrb1 binding agents and methods of use thereof